Abstract
This review provides a brief overview of the variety of carriers employed for targeted drug delivery used in cancer therapy and summarizes advantages and disadvantages of each approach. Particularly, the attention was paid to polymeric nanocarriers, liposomes, micelles, polyethylene glycol, poly(lactic-co-glycolic acid), dendrimers, gold and magnetic nanoparticles, quantum dots, silica nanoparticles, and carbon nanotubes. Further, this paper briefly focuses on several anticancer agents (paclitaxel, docetaxel, camptothecin, doxorubicin, daunorubicin, cisplatin, curcumin, and geldanamycin) and on the influence of their combination with nanoparticulate transporters to their properties such as cytotoxicity, short life time and/or solubility.
Keywords: Nanotechnologies, nanoparticles, gene therapy, anticancer drugs, drug carriers, cancer, cytostatic, targeted therapy.
Current Drug Metabolism
Title:Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Volume: 14 Issue: 5
Author(s): Jana Drbohlavova, Jana Chomoucka, Vojtech Adam, Marketa Ryvolova, Tomas Eckschlager, Jaromir Hubalek and Rene Kizek
Affiliation:
Keywords: Nanotechnologies, nanoparticles, gene therapy, anticancer drugs, drug carriers, cancer, cytostatic, targeted therapy.
Abstract: This review provides a brief overview of the variety of carriers employed for targeted drug delivery used in cancer therapy and summarizes advantages and disadvantages of each approach. Particularly, the attention was paid to polymeric nanocarriers, liposomes, micelles, polyethylene glycol, poly(lactic-co-glycolic acid), dendrimers, gold and magnetic nanoparticles, quantum dots, silica nanoparticles, and carbon nanotubes. Further, this paper briefly focuses on several anticancer agents (paclitaxel, docetaxel, camptothecin, doxorubicin, daunorubicin, cisplatin, curcumin, and geldanamycin) and on the influence of their combination with nanoparticulate transporters to their properties such as cytotoxicity, short life time and/or solubility.
Export Options
About this article
Cite this article as:
Drbohlavova Jana, Chomoucka Jana, Adam Vojtech, Ryvolova Marketa, Eckschlager Tomas, Hubalek Jaromir and Kizek Rene, Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine, Current Drug Metabolism 2013; 14 (5) . https://dx.doi.org/10.2174/1389200211314050005
DOI https://dx.doi.org/10.2174/1389200211314050005 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry Advances in Molecular Therapeutic Approaches to Patients with Malignant Gliomas
Current Signal Transduction Therapy The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?
Current Angiogenesis (Discontinued) Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Editorial (Hot Topic: Targeted Therapy of Malignant Brain Tumors)
Current Signal Transduction Therapy Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials
Current Topics in Medicinal Chemistry Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design